

88586

Access DB#

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Mike Mello Examiner #: 69404 Date: 3/7/03
 Art Unit: 1654 Phone Number 30 8-4230 Serial Number: 09/937,306
 Mail Box and Bldg/Room Location: CM-1 Results Format Preferred (circle): PAPER DISK E-MAIL
10 A03

If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Association of no-synthase inhibitors
 Inventors (please provide full names): Michel Auger, Jeremiah Hurnett,
Pierre-Etienne Chabir de Lassauviere

Earliest Priority Filing Date: 2/4/99

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Please Search the following
 highlighted compounds together and then
 search them separately and see
 if there is any common
 use of them separately.

Thanks

Mary Jane Ruhl
 Tech. Info. Specialist, STIC
 TC-1600
 CM-1, Room 6A-06
 Phone: 805-1155

RECEIVED
 MAR 10 2003
 LIBRARY
 (STIC)

BEST AVAILABLE COPY

STAFF USE ONLY

Type of Search

Vendors and cost where applicable

Searcher:	NA Sequence (#)	STN
Searcher Phone #:	AA Sequence (#)	Dialog
Searcher Location:	Structure (#)	Questel/Orbit
Date Searcher Picked Up:	Bibliographic	Dr. Link
Date Completed:	Litigation	Lexis/Nexis
Searcher Prep & Review Time:	Fulltext	Sequence Systems
Clerical Prep Time:	Patent Family	WWW/Internet
Online Time:	Other	Other (specify)

Inventor Search

Meller 09/937, 306


10/03/2003

=> d ibib abs hitstr 1-3

L8 ANSWER 1 OF 3 HCPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:6386 HCPLUS
DOCUMENT NUMBER: 136:69731
TITLE: Preparation of N-phenylthiophenecarboxamidines and
analogs as NO synthase and lipid peroxidation
inhibitors
INVENTOR(S): Chabrier de Lassauniere, Pierre Etienne;
Auvin, Serge; Bigg, Dennis; Auguet, Michel;
Harnett, Jeremiah
PATENT ASSIGNEE(S): Societe de Conseils de Recherches et d'Applications
Scientifiques (S.C.R.A.S.), Fr.
SOURCE: U.S., 63 pp., Cont.-in-part of U. S. Ser. No. 381,749.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6335445	B1	20020101	US 1999-456205	19991207
FR 2761066	A1	19980925	FR 1997-3528	19970324
FR 2761066	B1	20001124		
FR 2764889	A1	19981224	FR 1997-7701	19970620
FR 2764889	B1	20000901		
WO 9842696	A1	19981001	WO 1998-FR288	19980216
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 6340700	B1	20020122	US 1999-381749	19990922
US 2002007062	A1	20020117	US 2001-882264	20010615
US 2002045753	A1	20020418	US 2001-945782	20010904
US 2002042511	A1	20020411	US 2001-953682	20010917
PRIORITY APPLN. INFO.: FR 1997-3528 A 19970324 FR 1997-7701 A 19970620 WO 1998-FR288 W 19980216 US 1999-381749 A2 19990922 WO 1998-FR1250 W 19980615 US 1999-456205 A3 19991207 US 2001-882264 A3 20010615				

OTHER SOURCE(S): MARPAT 136:69731
GI



AB RZZ1Z2Z3N:C(NH2)R1 [I; R = H, (un)substituted C6H4OR3, indolyl, etc.; R1 = alkyl or (un)substituted (hetero)aryl; R3 = H, alkyl, etc.; Z = bond, CO, alkylene(carbonyl), CONH, etc.; Z1 = bond or heterocyclylene; Z2 = bond, alkylene(oxy), etc.; Z3 = (un)substituted phenylene] were prep'd. Thus, 4-(O2N)C6H4NH2 was amidated by 3,5-di-tert-butyl-4-hydroxybenzoic acid and the reduced product amidated by S-methyl-2-thiophenethiocarboximide hydroiodide to give title compd. II. Data for biol. activity of I were given.

IT 125978-95-2, NO synthase

RL: BSU (Biological study, unclassified); BIOL (Biological study) (mediated disorders; treatment; prepn. of N-phenylthiophenecarboxamidines and analogs as NO synthase and lipid peroxidn. inhibitors)

RN 125978-95-2 HCPLUS

CN Synthase, nitric oxide (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 3 HCPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:725626 HCPLUS

DOCUMENT NUMBER: 133:281650

TITLE: Novel lipoic acid derivatives, their preparation, and pharmaceutical compositions containing them

INVENTOR(S): Harnett, Jeremiah; Auguet, Michel; Chabrier, De Lassauniere Pierre-etienne

PATENT ASSIGNEE(S): Societe De Conseil de Recherches et d'applications Scientifiques (S.C.R.A.S., Fr.; Chabrier De Lassauniere, Pierre-Etienne

SOURCE: PCT Int. Appl., 51 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000059899	A1	20001012	WO 2000-FR814	20000331
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,				

DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 FR 2791677 A1 20001006 FR 1999-4132 19990402
 FR 2791677 B1 20010817
 FR 2805537 A1 20010831 FR 2000-2315 20000224
 EP 1169316 A1 20020109 EP 2000-918930 20000331
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO
 JP 2003505341 T2 20030212 JP 2000-609410 20000331
 PRIORITY APPLN. INFO.: FR 1999-4132 A 19990402
 FR 2000-2315 A 20000224
 WO 2000-FR814 W 20000331

OTHER SOURCE(S): MARPAT 133:281650
 GI



AB The invention concerns novel lipoic acid derivs. I [A = $(CH_2)_mNR_3CO(CH_2)_n$, $(CH_2)_mCONR_3(CH_2)_n$, $(CH_2)_mNR_3(CH_2)_n$, $(CH_2)_mCONR_3(CH_2)pCONR_4(CH_2)_n$, $(CH_2)_mNR_3CONR_4(CH_2)_n$, $(CH_2)_mNR_3CONR_4(CH_2)_m$; R1, R2, R3, R4 = H, linear or branched C1-6-alkyl; X = X1, $(CH_2)_q$; Y = N:C(B)NH2, Y1; R5 = H, C1-6-alkyl, $(CH_2)_mQ$; T = $(CH_2)_1Y$; Q = halogen, OH, CN, NH2, alkoxy, alkylthio, (di)alkylamino, 5- or 6-membered heterocycle contg. O, NR6, S; R6 = H, C1-6-alkyl; R7 = H, C1-6-alkyl; B = NR8R9, SR10; R8, R9 = H, linear or branched C1-6-alkyl, NO2; R10 = H, linear or branched C1-6-alkyl; i = 0 - 6; m, n = 0 - 6; p = 2 - 6; q = 0 - 6] and II (A, X, Y, R1, R2 as in I), which have an inhibiting action with respect to NO-synthase enzymes producing nitrogen monoxide NO and/or are agents enabling the regeneration of antioxidants or entities trapping reactive oxygen species (ROS) and intervening in a more general manner in the redox status of thiol groups. Thus, I [3-AXY = $(CH_2)_4CONHC_6H_4(NHC(2-thienyl):NH)-4$] was prep'd. from thioctic acid via amidation with N-Boc-1,4-phenylenediamine, followed by deprotection and condensation with S-methyl-2-thiophenethiocarboximide. I showed NO synthase inhibition (CI50 = 4.5 .mu.M) and oxidative stress protection (CE50 = 30 .mu.M).

IT 125978-95-2, NO synthase
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (prepn. of novel lipoic acid derivs. with NO synthase inhibition activity and pharmaceutical compns. contg. them)

RN 125978-95-2 HCAPLUS
 CN Synthase, nitric oxide (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 10102-43-9, Nitrogen monoxide, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (prepn. of novel lipoic acid derivs. with NO synthase inhibition activity and pharmaceutical compns. contg. them)

RN 10102-43-9 HCAPLUS
 CN Nitrogen oxide (NO) (8CI, 9CI) (CA INDEX NAME)

N==O

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 3 HCPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2000:725417 HCPLUS
 DOCUMENT NUMBER: 133:276363
 TITLE: Association of NO-synthase inhibitors and metabolic antioxidants
 INVENTOR(S): Auguet, Michel; Harnett, Jeremiah;
 Chabrier De Lassauniere, Pierre-etienne
 PATENT ASSIGNEE(S): Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S, Fr.
 SOURCE: PCT Int. Appl., 16 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000059448	A2	20001012	WO 2000-FR812	20000331
WO 2000059448	A3	20010308		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2791571	A1	20001006	FR 1999-4134	19990402
FR 2791571	B1	20021004		
EP 1169005	A2	20020109	EP 2000-915262	20000331
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
NO 2001004770	A	20011123	NO 2001-4770	20011001
PRIORITY APPLN. INFO.:			FR 1999-4134	A 19990402
			WO 2000-FR812	W 20000331

AB The invention relates to a pharmaceutical compn. comprising as an active ingredient one or several substances interfering with the synthesis of nitrogen monoxide by inhibiting NO-synthase and one or several metabolic antioxidants contg. thiol groups and intervening in the redox status of the thiol groups, and optionally a pharmaceutically acceptable support. The invention also relates to a product contg. one or several NO-synthase inhibitors and one or several metabolic antioxidants intervening in the redox status of the thiol groups, as a combined product in a sepd. form of said active ingredients. A mixt. of 3 mg/kg N-phenyl-2-thiophenecarboximidamine and 10 mg/kg lipoic acid increased the dopamine level in guinea pigs suffering from parkinson to 5.21 ng/mg nervous tissue which was higher than either compds.

IT 52-67-5D, Penicillamine, dimeric derivs. 74-79-3, L Arginine, biological studies 79-17-4, Aminoguanidine 306-60-5, Agmatine 616-91-1 1098-97-1, Pyritinol 2149-70-4, Nitroarginine 2214-67-7

2942-42-9, 7 Nitroindazole 2986-20-1, s-Ethylisothiourea
 3483-12-3, Dithiothreitol 3737-39-1 5401-94-5,
 5 Nitroindazole 7597-18-4, 6 Nitroindazole 17035-90-4
 22780-54-7, 2-Iminopiperidine 25371-96-4,
 1,2-(Trifluoromethylphenyl)imidazole 50903-99-6
 57828-26-9, Lipoic acid 57828-26-9D, Lipoic acid,
 derivs. 156719-41-4, S-Methyl-L-thiocitrulline
 158875-72-0, S-Ethyl-L-thiocitrulline 171082-82-9
 179555-23-8 194245-33-5 300357-99-7
 300358-00-3


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(assocn. of NO-synthase inhibitors and metabolic antioxidants)

RN 52-67-5 HCPLUS

CN D-Valine, 3-mercpto- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 74-79-3 HCPLUS


CN L-Arginine (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 79-17-4 HCPLUS

CN Hydrazinecarboximidamide (9CI) (CA INDEX NAME)



RN 306-60-5 HCPLUS


CN Guanidine, (4-aminobutyl)- (8CI, 9CI) (CA INDEX NAME)




RN 616-91-1 HCPLUS

CN L-Cysteine, N-acetyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 1098-97-1 HCAPLUS
 CN 4-Pyridinemethanol, 3,3'-[dithiobis(methylene)]bis[5-hydroxy-6-methyl-
 (9CI) (CA INDEX NAME)




RN 2149-70-4 HCAPLUS
 CN L-Ornithine, N5-[imino(nitroamino)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 2214-67-7 HCAPLUS
 CN 2H-Azepin-7-amine, 3,4,5,6-tetrahydro- (9CI) (CA INDEX NAME)




RN 2942-42-9 HCAPLUS
 CN 1H-Indazole, 7-nitro- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)




RN 2986-20-1 HCAPLUS

CN Carbamimidothioic acid, ethyl ester (9CI) (CA INDEX NAME)




RN 3483-12-3 HCAPLUS
 CN 2,3-Butanediol, 1,4-dimercapto-, (2R,3R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 3737-39-1 HCAPLUS
 CN 2-Thiophenecarboximidamide, N-phenyl- (9CI) (CA INDEX NAME)



RN 5401-94-5 HCAPLUS
 CN 1H-Indazole, 5-nitro- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)




RN 7597-18-4 HCAPLUS
 CN 1H-Indazole, 6-nitro- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)




RN 17035-90-4 HCAPLUS
 CN L-Ornithine, N5-[imino(methylamino)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 22780-54-7 HCAPLUS
 CN 2-Pyridinamine, 3,4,5,6-tetrahydro- (9CI) (CA INDEX NAME)




RN 25371-96-4 HCAPLUS
 CN 1H-Imidazole, 1-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 50903-99-6 HCAPLUS
 CN L-Ornithine, N5-[imino(nitroamino)methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 57828-26-9 HCAPLUS
 CN Lipoic acid (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
 RN 57828-26-9 HCAPLUS
 CN Lipoic acid (9CI) (CA INDEX NAME)


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
 RN 156719-41-4 HCAPLUS
 CN L-Ornithine, N5-[imino(methylthio)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 158875-72-0 HCAPLUS
 CN L-Ornithine, N5-[(ethylthio)iminomethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 171082-82-9 HCAPLUS
 CN 1H-Benzimidazole-1,2-diamine, N1-methyl- (9CI) (CA INDEX NAME)




RN 179555-23-8 HCAPLUS
 CN 2-Pyridineethanamine, 6-amino-4-methyl- (9CI) (CA INDEX NAME)




RN 194245-33-5 HCAPLUS
 CN 2-Pyrimidinamine, 1,4-dihydro- (9CI) (CA INDEX NAME)



RN 300357-99-7 HCAPLUS
 CN 2H-1,3-Thiazin-2-imine, 5,6-dihydro- (9CI) (CA INDEX NAME)




RN 300358-00-3 HCPLUS
 CN 2H-1,3-Oxazin-2-imine, 5,6-dihydro- (9CI) (CA INDEX NAME)




IT 56-87-1, Lysine, biological studies 70-26-8, Ornithine
 10102-43-9, Nitrogen monoxide, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (assocn. of NO-synthase inhibitors and metabolic antioxidants)
 RN 56-87-1 HCPLUS
 CN L-Lysine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 70-26-8 HCPLUS
 CN L-Ornithine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 10102-43-9 HCPLUS
 CN Nitrogen oxide (NO) (8CI, 9CI) (CA INDEX NAME)

N=O

IT 125978-95-2, NO-synthase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitors; assocn. of NO-synthase inhibitors and metabolic
 antioxidants)
 RN 125978-95-2 HCPLUS
 CN Synthase, nitric oxide (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***